Home/Pipeline/Qelbree® (viloxazine ER)

Qelbree® (viloxazine ER)

Attention-Deficit/Hyperactivity Disorder (ADHD)

Approved/CommercialMarketed

Key Facts

Indication

Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase

Approved/Commercial

Status

Marketed

Company

Supernus Pharmaceuticals

About Supernus Pharmaceuticals

Supernus Pharmaceuticals is a commercial-stage biopharma leader in CNS disorders, leveraging deep expertise in drug delivery and product development to build a diversified portfolio. The company has demonstrated consistent growth, earning recognition on lists like Forbes' America's Best Small Companies and Fortune's 100 Fastest Growing Companies. With a foundation of marketed products generating revenue, Supernus is strategically advancing mid- and late-stage pipeline candidates while maintaining a patient-centric culture and operational excellence.

View full company profile

Therapeutic Areas

Neurology Psychiatry Central Nervous System (CNS)

Other Attention-Deficit/Hyperactivity Disorder (ADHD) Drugs

Drug	Company	Phase	Status
JORNAY PM	Collegium Pharmaceutical	Approved/Commercial	Marketed
AZSTARYS	Collegium Pharmaceutical	Approved/Commercial	Acquisition Announced (Mar 2026)